Calliditas Therapeutics IPO Presentation Deck
Our lead indication: IgA Nephropathy - significant unmet medical need
PROFILE
Progressive autoimmune disease
Genetic predisposition - required but not sufficient;
environmental, bacterial, dietary factors
Normally diagnosed in ages 20-30
More prevalent in men than in women in the West
Up to 50% at risk of developing ESRD within 10-20
years
calliditas
Level of protein in the urine (proteinuria) is
correlated with traditional outcome measure of
kidney function (eGFR)
High levels of proteinuria indicate disease
progression and increased risk of ESRD
MAIN MARKETS
Treatment options
ESTIMATED PREVALENCE
130,000-150,000
Source: 1) Estimates in Greater China and Japan based in part on published prevalence among ethnic patient populations in U.S., analyses of prevalence in Europe and published incidence rates in certain geographies.
200,000
2,000,000¹
There is no approved treatment
Virtually all patients are prescribed blood pressure-lowering agents (ACES and ARBS)
*As disease progresses, systemic immunosuppressive agents, primarily consisting of high doses of systemic corticosteroids are used by some nephrologists
Randomized trials involving these off-label immunosuppressant treatments have either failed to show efficacy or shown severe metabolic and infectious side effects, including
mortality
180,000¹
June 2020
8View entire presentation